Overall, higher numbers of CD4+ and CD8+ cells have been shown to be predictive of better outcomes in patients with advanced NSCLC treated with ICIs [45,46] as well as the presence of tertiary lymphoid structures [47,48]. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.